

Osteoporosis References

1. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 87. January 2005. National Institute for Clinical Excellence (NICE). ISBN 1-84257-872-3.
2. Osteoporosis a potentially disabling bone disease. Don't let your bones reach Breaking Point. Booklet.
http://www.breakingpoint.ie/breaking_point_brochure.pdf. Accessed 22nd February 2006.
3. Klotzbuecher C M et al. Patients with prior fractures have an increased risk of future fractures. A summary of the literature and statistical synthesis. Journal of Bone & Mineral Research 2000; 15 (4): 721-727.
4. Hosking D, Lippuner K, Turpin J, et al. An international study of the prevalence of vitamin D inadequacy among community dwelling women with osteoporosis. Presented at: 5th Annual Meeting of the European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO), 16-19 March 2005; Rome, Italy.